Monoclonal IgM Antibodies Targeting Candida albicans Hyr1 Provide Cross-Kingdom Protection Against Gram-Negative Bacteria.

Frontiers in Immunology
Eman G YoussefAshraf S Ibrahim

Abstract

Recent years have seen an unprecedented rise in the incidence of multidrug-resistant (MDR) Gram-negative bacteria (GNBs) such as Acinetobacter and Klebsiella species. In view of the shortage of novel drugs in the pipeline, alternative strategies to prevent, and treat infections by GNBs are urgently needed. Previously, we have reported that the Candida albicans hypha-regulated protein Hyr1 shares striking three-dimensional structural homology with cell surface proteins of Acinetobacter baumannii. Moreover, active vaccination with rHyr1p-N or passive immunization with anti-Hyr1p polyclonal antibody protects mice from Acinetobacter infection. In the present study, we use molecular modeling to guide design of monoclonal antibodies (mAbs) generated against Hyr1p and show them to bind to priority surface antigens of Acinetobacter and Klebsiella pneumoniae. The anti-Hyr1 mAbs block damage to primary endothelial cells induced by the bacteria and protect mice from lethal pulmonary infections mediated by A. baumannii or K. pneumoniae. Our current studies emphasize the potential of harnessing Hyr1p mAbs as a cross-kingdom immunotherapeutic strategy against MDR GNBs.

References

Apr 1, 1985·The Journal of Infectious Diseases·R B FickH Y Reynolds
Mar 25, 1981·Journal of Molecular Biology·T F Smith, M S Waterman
Feb 26, 1998·American Journal of Respiratory and Critical Care Medicine·J L TrouilletC Gibert
Apr 3, 2002·The EMBO Journal·Ulrich von Pawel-RammingenLars Björck
May 7, 2004·The Journal of Biological Chemistry·Donald C SheppardJohn E Edwards
Jul 21, 2004·Journal of Computational Chemistry·Eric F PettersenThomas E Ferrin
Feb 9, 2005·American Journal of Respiratory and Critical Care Medicine·UNKNOWN American Thoracic Society, UNKNOWN Infectious Diseases Society of America
Jul 25, 2007·Antimicrobial Agents and Chemotherapy·Federico PerezRobert A Bonomo
Sep 26, 2007·Epidemiology and Infection·M E FalagasK Z Vardakas
Jul 16, 2008·Clinical Microbiology Reviews·Anton Y PelegDavid L Paterson
Nov 22, 2008·The Lancet Infectious Diseases·Drosos E Karageorgopoulos, Matthew E Falagas
Jan 23, 2009·FEMS Immunology and Medical Microbiology·Lin LinBrad Spellberg
Jun 16, 2009·Emerging Infectious Diseases·Yohei DoiDavid L Paterson
Aug 5, 2009·Intensive Care Medicine·Anselmo CaricatoMassimo Antonelli
Oct 29, 2009·Infection Control and Hospital Epidemiology : the Official Journal of the Society of Hospital Epidemiologists of America·Ebbing LautenbachMyoung Kim
Dec 10, 2009·The Journal of Antimicrobial Chemotherapy·Paul G HigginsHarald Seifert
Dec 25, 2009·Infection Control and Hospital Epidemiology : the Official Journal of the Society of Hospital Epidemiologists of America·Marc S HoffmannRamanan Laxminarayan
Feb 24, 2010·American Journal of Infection Control·Victor D RosenthalUNKNOWN INICC Members
Apr 27, 2010·The Journal of Infectious Diseases·Guanpingsheng LuoYue Fu
Nov 10, 2011·Toxins·Zhaochun ChenRobert Purcell
Dec 21, 2013·The Journal of Clinical Investigation·Teclegiorgis GebremariamAshraf S Ibrahim
Jan 1, 2014·Antimicrobial Agents and Chemotherapy·Younes SmaniJerónimo Pachón
Aug 3, 2014·Microbial Pathogenesis·Shakiba Darvish Alipour AstanehSeyed Latif Mousavi Gargari
Oct 14, 2014·Frontiers in Immunology·Michael R YeamanJohn P Hennessey
Dec 10, 2014·Proceedings of the National Academy of Sciences of the United States of America·Michael R YeamanAshraf S Ibrahim
Dec 31, 2014·Nature Methods·Jianyi YangYang Zhang
May 8, 2015·Nature Protocols·Lawrence A KelleyMichael J E Sternberg
Jun 17, 2016·Microbiology and Molecular Biology Reviews : MMBR·Michelle K Paczosa, Joan Mecsas
Aug 31, 2016·Advances in Experimental Medicine and Biology·D PrzybyłowskaE Mierzwińska-Nastalska
Jan 8, 2017·Annual Review of Pharmacology and Toxicology·Michael R Yeaman, John P Hennessey
Jan 26, 2017·The New England Journal of Medicine·Mark H WilcoxUNKNOWN MODIFY I and MODIFY II Investigators
Feb 16, 2017·Frontiers in Bioscience (Elite Edition)·Shakiba Darwish Alipour AstanehSeyed Latif Mousavi Gargari
Jul 30, 2017·The Oncologist·Jeroen J M A HendrikxJos H Beijnen

❮ Previous
Next ❯

Citations

Feb 9, 2021·Expert Review of Vaccines·Crystal Ma, Wangxue Chen

❮ Previous
Next ❯

Methods Mentioned

BETA
flow cytometry
ELISA
electrophoresis

Software Mentioned

Phyre
CLUSTALW
Chimera
RasMol
Quark
iTasser

Related Concepts

Related Feeds

Candida albicans

Candida albicans is an opportunistic, fungal pathogen of humans that frequently causes superficial infections of oral and vaginal mucosal surfaces of debilitated and susceptible individuals. Discover the latest research on Candida albicans here.

Acinetobacter Infections

Acinetobacter infections have become common in hospitalized patients, especially in the intensive care unit setting and are difficult to treat due to their propensity to develop antimicrobial drug resistance. Discover the latest research on Acinetobacter Infections here.

Candidiasis

Candidiasis is a common fungal infection caused by Candida and it can affect many parts for the body including mucosal membranes as well as the gastrointestinal, urinary, and respiratory tracts. Here is the latest research.

Candidiasis (ASM)

Candidiasis is a common fungal infection caused by Candida and it can affect many parts for the body including mucosal membranes as well as the gastrointestinal, urinary, and respiratory tracts. Here is the latest research.